Shore ND - Search Results

1

Development and evaluation of the MiCheck test for aggressive prostate cancer.

Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt D, Chan DW, Campbell DH, Walsh BJ. Shore ND, et al. Urol Oncol. 2020 Aug;38(8):683.e11-683.e18. doi: 10.1016/j.urolonc.2020.03.010. Epub 2020 Apr 16. Urol Oncol. 2020. PMID: 32305266

2

A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.

Shore ND, Concepcion R, Barocas DA. Shore ND, et al. Hosp Pract (1995). 2013 Oct-Nov;41(4):78-80. doi: 10.3810/hp.2013.10.1083. Hosp Pract (1995). 2013. PMID: 24145592

3

Infusion therapy and implantables for the urologist.

Rothschild J, Thompson IM 3rd, Concepcion RS, Shore ND. Rothschild J, et al. Among authors: shore nd. Urol Clin North Am. 2013 Nov;40(4):591-8. doi: 10.1016/j.ucl.2013.07.014. Urol Clin North Am. 2013. PMID: 24182978 Review.

4

A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.

Ryan C, Shore ND, Concepcion R. Ryan C, et al. Among authors: shore nd. Postgrad Med. 2013 Nov;125(6):114-6. doi: 10.3810/pgm.2013.11.2718. Postgrad Med. 2013. PMID: 24200767

5

Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer.

Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, Lewine N, Gustavsen G, Pothier K, Brawer MK. Shore N, et al. Curr Med Res Opin. 2014 Apr;30(4):547-53. doi: 10.1185/03007995.2013.873398. Epub 2013 Dec 23. Curr Med Res Opin. 2014. PMID: 24320750

6

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Mouraviev V, Mariados N, Albala D, Concepcion RS, Shore ND, Sims RB, Emberton M, Pieczonka CM. Mouraviev V, et al. Among authors: shore nd. Rev Urol. 2014;16(3):122-30. Rev Urol. 2014. PMID: 25337042 Free PMC article. Review.

7

A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM. Parekh DJ, et al. Among authors: shore nd. Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27. Eur Urol. 2015. PMID: 25454615

8

Management of early-stage prostate cancer.

Shore N. Shore N. Am J Manag Care. 2014 Dec;20(12 Suppl):S260-72. Am J Manag Care. 2014. PMID: 25734965 Free article. Review.

9

Avoiding obsolescence in advanced prostate cancer management: a guide for urologists.

Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. Shore ND, et al. BJU Int. 2015 Feb;115(2):188-97. doi: 10.1111/bju.12665. BJU Int. 2015. PMID: 25756134 Review.

10

Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.

Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED. Shore ND, et al. BJU Int. 2017 Feb;119(2):239-244. doi: 10.1111/bju.13482. Epub 2016 Apr 16. BJU Int. 2017. PMID: 26991743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page